Want to see HK:1951 full AI Analyst Report?
Top Page
Jinxin Fertility Group Ltd.
(1951)
Select Model
Select Model
Rating:54Neutral
Price Target:
HK$2.00
▼(-11.89% Downside)
Action:Reiterated
Date:10/18/26
The score is held back primarily by weakening financial performance—especially the 2025 net loss, negative revenue growth, and softer free cash flow—despite a manageable leverage profile and positive operating cash flow. Technical indicators are mildly supportive in the near term but still constrained by being below the 200-day average. Valuation appears neither clearly attractive nor severely stretched, with only a modest dividend yield.
Positive Factors
Manageable Leverage
Manageable leverage and substantial equity provide Jinxin Fertility with balance-sheet flexibility as it operates through changing demand and profitability. Lower financial strain can preserve capacity to fund clinical operations, maintain services, and pursue growth without excessive dependence on borrowing.
Negative Factors
Revenue Contraction
A revenue decline after stronger expansion in 2021–2022 signals weakening momentum in the company’s fertility-services activity. Prolonged contraction would reduce operating leverage, make fixed clinical costs harder to absorb, and constrain the resources available for investment and expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable Leverage
Manageable leverage and substantial equity provide Jinxin Fertility with balance-sheet flexibility as it operates through changing demand and profitability. Lower financial strain can preserve capacity to fund clinical operations, maintain services, and pursue growth without excessive dependence on borrowing.
Read all positive factors
Jinxin Fertility Group Ltd. (1951) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.11B
Dividend Yield1.84%
Average Volume (3M)9.04M
Price to Earnings (P/E)26.8
Beta (1Y)0.67
Revenue Growth6.52%
EPS GrowthN/A
CountryHK
Employees3,128
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.07
Shares Outstanding2,705,044,000
10 Day Avg. Volume8,242,946
30 Day Avg. Volume9,044,526
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.64
Price to Sales (P/S)2.27
P/FCF Ratio26.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$3.35Price Target Upside47.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$2.85B
Jinxin Fertility Group Ltd. Business Overview & Revenue Model
Company Description
Jinxin Fertility Group Limited is an investment holding company that specializes in providing assisted reproductive services (ARS) across both China and the United States. Its core offerings primarily include two types of treatment: artificial ins...
How the Company Makes Money
The company primarily makes money by providing fertility and assisted reproductive services to patients, generating revenue from fees charged for clinical consultations, diagnostic testing, and treatment procedures related to infertility care. A k...
Jinxin Fertility Group Ltd. Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
63
Positive
Cash Flow
56
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.69B | 2.58B | 2.81B | 2.79B | 2.36B | 1.84B |
| Gross Profit | 947.47M | 818.44M | 1.10B | 1.18B | 913.13M | 771.48M |
| EBITDA | 655.61M | 542.45M | 717.90M | 765.20M | 545.37M | 540.56M |
| Net Income | 168.59M | -950.88M | 283.10M | 344.72M | 121.12M | 339.90M |
Balance Sheet | ||||||
| Total Assets | 13.82B | 13.97B | 14.98B | 14.90B | 15.23B | 12.83B |
| Cash, Cash Equivalents and Short-Term Investments | 804.61M | 906.17M | 570.82M | 852.90M | 1.40B | 1.93B |
| Total Debt | 3.00B | 2.96B | 2.71B | 2.55B | 4.16B | 2.09B |
| Total Liabilities | 4.86B | 4.77B | 4.63B | 4.71B | 6.50B | 4.07B |
| Stockholders Equity | 8.91B | 9.15B | 10.27B | 10.09B | 8.64B | 8.55B |
Cash Flow | ||||||
| Free Cash Flow | 226.18M | 218.33M | 489.30M | 510.92M | -417.65M | 263.62M |
| Operating Cash Flow | 463.80M | 475.94M | 629.20M | 684.48M | 541.74M | 343.45M |
| Investing Cash Flow | -180.25M | -154.86M | -293.27M | -375.04M | -1.38B | -1.57B |
| Financing Cash Flow | -215.87M | -6.66M | -458.29M | -950.45M | 460.14M | 955.05M |
Jinxin Fertility Group Ltd. Technical Analysis
Positive
2.27
Price Trends
2.20
Positive
2.16
Positive
2.26
Positive
Market Momentum
0.02
Negative
55.52
Neutral
72.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1951, the sentiment is Positive. The current price of 2.27 is above the 20-day moving average (MA) of 2.24, above the 50-day MA of 2.20, and above the 200-day MA of 2.26, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 55.52 is Neutral, neither overbought nor oversold. The STOCH value of 72.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1951.
Jinxin Fertility Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | HK$5.84B | 27.81 | 2.55% | 0.39% | 1.59% | -58.55% | |
54 Neutral | HK$6.11B | 26.75 | 1.87% | 1.84% | 6.52% | ― | |
52 Neutral | HK$1.10B | 78.10 | 0.48% | 1.10% | -3.26% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$931.99M | -18.57 | -1.56% | 10.61% | 7.95% | 60.86% | |
43 Neutral | HK$489.79M | -2.69 | -8.65% | ― | 47.93% | 65.94% |
* Healthcare Sector Average
HK:1951
Jinxin Fertility Group Ltd.
2.27
-0.14
-5.69%
HK:9960
Kindstar Globalgene Technology, Inc.
0.90
-0.30
-25.42%
HK:3886
Town Health International Medical Group Ltd.
0.16
-0.11
-40.07%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
9.51
-3.57
-27.33%
HK:2453
Concord Healthcare Group Co., Ltd. Class H
0.63
-1.92
-75.39%
Jinxin Fertility Group Ltd. Corporate Events
Jinxin Fertility Steps Up Buybacks and Sets Higher Dividend Targets Under 2026–2028 Return Plan
Oct 2, 2026
Jinxin Fertility Group Limited has updated investors on the execution of its shareholder return plan covering 2026 to 2028, under which it aims to return 50% to 80% of non-IFRS adjusted EBITDA via share repurchases and dividends. Over the past 12 ...
Jinxin Fertility Plans RMB1.93 Billion ABS Issue Backed by Hengyu Assets
Sep 29, 2026
Jinxin Fertility Group Limited, a Cayman Islands-incorporated and Hong Kong-listed provider of fertility and assisted reproductive services, is leveraging its healthcare property assets to support expansion of its mainland China operations. Subsid...
Jinxin Fertility to Build Women’s Health Translational Medicine Platform
Sep 9, 2026
Jinxin Fertility Group is expanding beyond its core assisted reproductive services by developing a translational medicine platform focused on women’s health, particularly ovarian ageing, diminished ovarian function, and related reproductive ...
Jinxin Fertility Swings Back to Profit on Rising Revenue and Strong Adjusted Earnings
Aug 21, 2026
Jinxin Fertility Group Limited, a specialized fertility and assisted reproductive healthcare provider incorporated in the Cayman Islands, reported improved results for the six months ended June 30, 2026. The company generates revenue primarily fro...
Jinxin Fertility Sets August Board Meeting to Approve Interim Results
Aug 7, 2026
Jinxin Fertility Group Limited has scheduled a board meeting for August 21, 2026 to review and approve the group’s interim results for the six months ended June 30, 2026 and to authorize their publication. The announcement signals that the c...
Jinxin Fertility Posts Solid Growth in Fertility and Obstetrics Services for H1 2026
Jul 21, 2026
Jinxin Fertility Group reported that new patient visits for infertility rose 9.1% to 24,169 and oocyte pick up cycles increased 6.1% to 14,653 in the first half of 2026, underscoring steady growth in demand for its core reproductive services. The ...
Jinxin Fertility Signals Sharp Profit Turnaround on Recovery in Core Markets
Jul 21, 2026
Jinxin Fertility Group Limited has issued a positive profit alert, forecasting a swing from a net loss of about RMB1.04 billion in the first half of 2025 to a net profit of at least RMB90 million in the first half of 2026. The group also expects E...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.